Oncology

Defying cancer

Our defiant goal is to reverse the cancer mortality trend. We’re doing this through a comprehensive pipeline that addresses the hallmarks of cancer. With an emphasis on immuno-oncology and antibody drug conjugates (ADCs), we are applying multiple approaches to activate the immune system to search and destroy cancer, and delivering highly-potent warheads directly to the tumor cell.




Our Pipeline

Oncology

Phase 1

Phase 1

  • Imfinzi (durvalumab) + AZD1775 solid tumours
  • Imfinzi (durvalumab) + Iressa non-small cell lung cancer
  • Imfinzi (durvalumab) + MEDI0562 solid tumours
  • Imfinzi (durvalumab) + MEDI9197 solid tumours
  • Imfinzi (durvalumab) + MEDI9447 solid tumours
  • Imfinzi (durvalumab) + dabrafenib + trametinib melanoma
  • Imfinzi (durvalumab) + monalizumab solid tumours
  • Imfinzi (durvalumab) + selumetinib solid tumours
  • Imfinzi (durvalumab) + tremelimumab solid tumours
  • Imfinzi (durvalumab) or Imfinzi (durvalumab) + (tremelimumab or AZD9150) diffuse large B-cell lymphoma
  • MEDI-565 solid tumours
  • MEDI0562 solid tumours
  • MEDI0680 solid tumours
  • MEDI1873 solid tumours
  • MEDI3726 prostate cancer
  • MEDI4276 solid tumours
  • MEDI5083 solid tumours
  • MEDI7247 haematological malignancies
  • MEDI9197 solid tumours
  • MEDI9447 solid tumours
  • tremelimumab + MEDI0562 solid tumours

Phase 2

Phase 2

  • Imfinzi (durvalumab) solid tumours
  • Imfinzi (durvalumab) + AZD5069 pancreatic ductal adenocarcinoma
  • Imfinzi (durvalumab) + AZD5069 Imfinzi (durvalumab) + AZD9150 head and neck squamous cell carcinoma
  • Imfinzi (durvalumab) + MEDI0680 solid tumours
  • Imfinzi (durvalumab) + tremelimumab hepatocellular carcinoma (liver cancer)
  • Imfinzi (durvalumab) + tremelimumab gastric cancer
  • MEDI-573 metastatic breast cancer

Phase 3

Phase 3

  • Imfinzi (durvalumab) + tremelimumab ARCTIC 3rd-line non-small cell lung cancer
  • Imfinzi (durvalumab) + tremelimumab CASPIAN 1st-line small cell lung cancer
  • Imfinzi (durvalumab) + tremelimumab DANUBE 1st-line bladder cancer
  • Imfinzi (durvalumab) + tremelimumab EAGLE 2nd-line head and neck squamous cell carcinoma
  • Imfinzi (durvalumab) + tremelimumab KESTREL 1st-line head and neck squamous cell carcinoma
  • Imfinzi (durvalumab) + tremelimumab MYSTIC 1st-line non-small cell lung cancer
  • Imfinzi (durvalumab) + tremelimumab NEPTUNE 1st-line non-small cell lung cancer
  • Imfinzi (durvalumab) + tremelimumab + chemotherapy POSEIDON 1st-line non-small cell lung cancer
  • moxetumomab pasudotox PLAIT hairy cell leukaemia

Oncology News

Join us at MedImmune

Our Great Place to Work strategic initiative offers a dynamic environment that fosters collaboration and innovation. We attract top minds, and we do what it takes to nurture and build talent.